Topol says the unpublished results to which Wolfe is pointing don't pass the high bar of clinical proof--even though Celebrex may still pose a heart risk, and Pfizer may not have appropriately disclosed the results.
He and his wife quickly realized they had mountains of products from which to tear off the bar codes needed to submit for proof of purchase by the offer deadline, but he was unstoppable.